The pan-Canadian Pharmaceutical Alliance engaged the Canadian Agency for Drugs and Technologies in Health to lead a multiphase stakeholder consultation process to encourage biosimilar uptake.
Canadian provinces are moving to adopt biosimilars in publicly funded drug plans, and in early 2020, the pan-Canadian Pharmaceutical Alliance (pCPA) will receive a stakeholder report intended to increase uptake even further.
pCPA engaged the Canadian Agency for Drugs and Technologies in Health (CADTH) to lead a multiphase stakeholder consultation process. The project started a few months ago with more than 20 key informant interviews, centered around 5 clinical areas: dermatology, endocrinology, gastroenterology, ophthalmology, and rheumatology.
Stakeholders include clinicians, patient group leaders, private payers, group purchasing organizations, and industry representatives; the project aims to ensure that their perspectives about biosimilars can be captured and conveyed to policymakers.
Last month, there was a 1-day meeting focused on 2 sessions. The morning session featured presentations and discussions for both originator and biosimilar industry representatives. Later in the day, clinicians and patients met without industry present.
During the meeting, participants discussed various policy options designed to increase uptake of biosimilars, including new starts only, tiering, quotas, non-medical switching, and tendering.
Last week, Alberta became the latest province to mandate a non-medical switch to biosimilars, joining British Columbia and Manitoba. Ontario is also considering the same move.
In 2017, pCPA engaged Cancer Care Ontario to lead a pan-Canadian Oncology Biosimilars Initiative, another stakeholder engagement process with the goal of ensuring that the implementation and use of therapeutic oncology biosimilars are appropriate and cost-effective across Canada.
Last year, the pCPA published the Biologics Policy Directions and pCPA Negotiations document with the goal of developing a clear and consistent pan-Canadian approach to biologic medicines across Canada for both originator products and biosimilars.
The final report will be provided to pCPA and its member jurisdictions in early 2020.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.